NuCana plc
NCNANASDAQHealthcareBiotechnology
Previous close
$1.52
−$0.01 · -0.65%
NCNA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
46
Fair Value
Momentum
25
Weakening
Sentiment
56
Mixed
Risk resilience
14
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteNuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- GB
- CEO
- Hugh Stephen Griffith
- Listed since
- Sep 28, 2017
- Employees
- 11
Market position
Day range
Current $1.52
52-week range
Current $1.52
- Open
- $1.53
- Previous close
- $1.53
- Volume
- 18.57K
- 0.42× average
- Average volume
- 44.43K
- Average daily volume
- Market cap
- 9.23M USD
- Beta
- 2.22
- Market reference 1
- 50-day average
- $1.4763
- +2.96% above average
- 200-day average
- $2.351
- -35.35% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -0.44×
- P/B (TTM)
- 0.23×
- P/S (TTM)
- 0×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
Financial health
- Debt / equity
- 0.03×
- Altman Z-score
- -14.09
- Piotroski F-score
- 3 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (GBP) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 12.74M GBP | 18.02M GBP | 25.06M GBP | 36.43M GBP | 36.83M GBP |
| Selling, general, and administrative | 8.1M GBP | 4.99M GBP | 6.06M GBP | 7.29M GBP | 8.53M GBP |
| Operating expenses | 20.11M GBP | 22.9M GBP | 31.13M GBP | 43.72M GBP | 45.36M GBP |
| Interest income | 386K GBP | 358K GBP | 754K GBP | 669K GBP | 103K GBP |
| Interest expense | — | — | 1.1M GBP | — | — |
| Depreciation and amortization | 274K GBP | 522K GBP | 575K GBP | 732K GBP | 942K GBP |
| Operating income | −20.11M GBP | −22.81M GBP | −32.78M GBP | −43.7M GBP | −45.35M GBP |
| Net income | −29.35M GBP | −19M GBP | −27.63M GBP | −32.02M GBP | −40.53M GBP |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 64%
- 7 beats, 4 misses, 0 met estimates
- Average EPS surprise
- -7002.78%
- 11 comparable reports
- Latest EPS result
- -0.99
- Estimate -2.65 · Beat by 62.66%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
8 ratingsRecent analyst actions
NCNA news
NCNA peers
Continue in GoAI
Research NCNAresearch.disclaimer